Tuesday, 04 Nov 2025

MedPulse360

AAIC 2025: Top Interviews and Key Takeaways
13 September, 2025

Ianalumab Meets Primary End Points in Phase 3 NEPTUNUS Trials of Sjögren’s Disease
13 September, 2025

Targeting Amyloid-ß Oligomers With Investigational Alzheimer Disease Therapy Valiltramiprosate
13 September, 2025

NeuroVoices: Howard Fillit, MD, on AAIC 2025 Highlights in Alzheimer Disease Prevention, Biomarkers, and Therapeutics
13 September, 2025

CPAP Treatment of OSA and Residual EDS Symptoms
13 September, 2025

Managing EDS in Patients With OSA and Accessing Therapy Effectiveness
13 September, 2025

Larger, More Controlled Studies Needed to Confirm Genistein’s Potential to Curve Alzheimer Cognition
13 September, 2025

Overviewing Promising Large-Scale Data on GLP-1 RAs in Idiopathic Intracranial Hypertension: Dennis Rivet, MD
13 September, 2025

Soluble CD83 Levels Reduced in NMOSD and Relapsing MOGAD, Pointing to Potential Biomarker
13 September, 2025

FDA Action Update, July 2025: Approval, Label Update, Complete Response Letter
13 September, 2025
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago